Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration

Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness with several intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents available for its management such as aflibercept, bevacizumab, and ranibizumab. However, direct comparisons between these three age...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-05, Vol.15 (5), p.e0232353
Hauptverfasser:	Eng, Victor A, Rayess, Nadim, Nguyen, Huy V, Leng, Theodore
Format:	Artikel
Sprache:	eng
Schlagworte:	Aflibercept Age Age related diseases Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Atrophy Bevacizumab Bevacizumab - therapeutic use Biology and Life Sciences Blindness Drug approval Endothelial growth factors Endothelium Epithelium Eye Eye diseases Female Follow-Up Studies Growth factors Growth rate Humans Image Interpretation, Computer-Assisted Intravitreal Injections Macular degeneration Male Medical research Medicine Medicine and Health Sciences Monoclonal antibodies Ophthalmic agents Optical Coherence Tomography Patients Pegaptanib Physiological aspects Ranibizumab Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Regression analysis Regression models Research and Analysis Methods Retina Retinal degeneration Retinal Degeneration - diagnostic imaging Retinal Degeneration - drug therapy Retinal Degeneration - pathology Retinal pigment epithelium Retinal Pigment Epithelium - diagnostic imaging Retinal Pigment Epithelium - drug effects Retinal Pigment Epithelium - pathology Retrospective Studies Social Sciences Statistical analysis Studies Tomography Tomography, Optical Coherence Treatment Outcome Variance analysis Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!